- Initial funding of up to $34 million for the project “Gene Mabs: A Scalable, Economic, Gene-Encoded Protective Antibody Platform Against Coronavirus” (HR0011-21-9-0015) to support the development of an STI-2020-encoded Gene MAbTM through Phase 2 clinical studies.
- STI-2020-encoded Gene MAb is in development for intramuscular injection against the SARS-CoV-2 virus and its variant strains to produce potent STI-2020 nAbs in the body.
- STI-2020-encoded Gene MAb products can potentially be stored at refrigerator temperatures, avoiding some of the cold chain management challenges associated with the deployment of COVID-19 vaccines currently in development.
- Sorrento has a cGMP facility in place to meet initial production demand and Sorrento expects that STI-2020-encoded Gene MAb can be produced in large quantity to meet potentially high demand.
Strategic Initiative
Slingshot members are tracking this corporate initiative:
DARPA and JPEO Award Contract to SmartPharm, a Subsidiary of Sorrento (SRNE), for Development of Rapid Countermeasure Against COVID-19 Using Gene-Encoded Neutralizing Antibodies
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| SRNE |
|
|
||||
Additional Information
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date: Nov 27, 2020 Projected Implementation: Q4, 2020 Relevance Tracked Until: Q1, 2021
Related Projects
-
Don’t see a project related to the strategic initiative you care about?
Related Keywords
Gene-encoded Neutralizing Antibodies, Sti-2020
